Inside J&J’s New Initiative to ‘Intercept’ Diseases

The pharmaceutical industry typically develops new drugs to help manage diseases.  But a new project inside Johnson & Johnson posits a different model: what if you could identify people at risk of developing a disease, and create products to stave it off? Ben Wiegand, head of the Disease Interception Accelerator, explains what they’re up to.

How business units get involved with J&J’s network of innovation centers

When J&J makes a new investment in a startup, “50 percent of the deal funding from J&J Innovation, and the business unit provides the other 50 percent,” explains Darren Snellgrove, Chief Financial Officer for J&J Innovation. “We have found that both sides having skin in the game, and a say in the decision making is an important component of success.” More insights inside…

How J&J is building its global network of innovation centers

The healthcare giant, headquartered in New Jersey, is opening innovation centers in Silicon Valley, Shanghai, London, and Boston. Robert Urban, who heads the Boston Innovation Center for Johnson & Johnson, explains how it is staffed; his mandate; and J&J’s new thinking around collaborating with healthcare startups. Includes an audio interview with Urban and a look at the Boston office.